Additional Targets Clause Samples

Additional Targets. Pfizer shall have the right to add up to two (2) additional Targets (in addition to the Second Target and any Replacement Target designated pursuant to Sections 2.1.3 and 2.1.5, respectively), exercisable upon written notice to CytomX, at any time prior to the three year anniversary (“Target Expansion Window”) of the Effective Date, subject to availability of such Target and payment of the Additional Target Fee, if applicable, as specified in Section 2.1.8.

Additional Targets. (a) Within ninety (90) days prior to the commencement of the second 12-month period of the Research Program, ImClone may add up to *** relating to ImClone's Areas of Interest to the Collaboration by notifying CombiChem in writing that it wishes to designate such Target(s) as Additional Target(s); it being understood that the Project Team shall be obligated to simultaneously work on no more than *** Collaboration Targets as directed by the RMC. (b) If CombiChem has already committed to working on a proposed Additional Target or has delivered a term sheet to any Third Party and remains in discussions to enter into a binding agreement with such Third Party with respect to the proposed Target at the time of notification, CombiChem shall inform ImClone that such proposed Additional Target is not available. Otherwise, the RMC shall establish the specific scientific achievements (to be mutually agreed between CombiChem and ImClone) for such Target and the same shall be designated as an Additional Target for the Collaboration and subject to the terms (including the commercial terms) of this Agreement.

Additional Targets. Commencing upon a Potential Target becoming an Additional Target in accordance with Section 2.2(a) (Grant of Option), Selecta hereby grants to Spark an exclusive (even as to Selecta and its Affiliates) right and license in the Field in the Territory, with the right to grant sublicenses, under the Selecta IP (i) to use, offer for sale, sell, import and otherwise Develop and Commercialize Licensed Products directed to such Additional Target, (ii) to make, have made and otherwise Manufacture Licensed Products directed to such Additional Target excluding the making, having made or Manufacturing of any Licensed Particles within such Licensed Products and (iii) contingent upon exercise of the Technology Transfer Option, make, have made and otherwise Manufacture Licensed Particles solely for inclusion in Licensed Products directed to such Additional Target and solely in accordance with Section 5.3 (Manufacturing Transfer).

Additional Targets. At any time during the Research Term, the parties may wish to expand the scope of the Research Program to cover targets in addition to the Targets. The parties shall determine in good faith negotiations whether they can agree on the terms of a separate agreement which shall cover the discovery, development and commercialization of compounds acting on those additional targets; provided, however, neither party shall be obligated to enter into such negotiations or to reach agreement if negotiations are conducted.

Additional Targets. In the event that the Selected Target Threshold has been reached, Novartis may from time to time during the Selection Term either: (i) upon written notice to Alnylam, withdraw (for any reason) a B List Target from treatment as a Selected Target. Thereafter Novartis shall be free to designate substitute Targets pursuant to Section 2.1(a) at any time, up to the Selected Target Threshold (for the avoidance of doubt, such substitute Targets shall not be considered "Supplemental Targets"); or (ii) deliver to the Gatekeeper one or more lists of additional Target(s) (each such list, a "Supplemental Target List"). Within two (2) days following the Gatekeeper's receipt of a Supplemental Target List, the Gatekeeper shall notify Novartis in writing (a "Supplemental Target Response Notice") which, if any, of the Targets identified on such Supplemental Target List are on the Blocked Target List most recently delivered by Alnylam to the Gatekeeper. All of the Targets on the Supplemental Target List that are not are on such Blocked Target List (each such Target, a "Supplemental Target"), shall be deemed "Selected Target(s)" for the purposes of this Agreement, and the Gatekeeper shall notify both Parties of the identity of such Supplemental Targets within the same two (2) day time period. Novartis shall pay, or cause to be paid, the payment set forth in Section 4.3(a). Novartis may designate no more than [**] Supplemental Targets in the aggregate (the "Supplemental Target Threshold").

Additional Targets. In connection with MAGENTA exercising its Exclusive Research Option Right for Targets other than the Initial Targets, MAGENTA shall follow the notification and selection procedures set forth in Section 3.3.3 with respect to such Targets (such Targets, once MAGENTA has exercised its Exclusive Research Option Right with respect thereto, together with the Initial Targets, the “Exclusive Research Targets”). In connection with MAGENTA’s exercise of its Exclusive Research Option Right for such other Targets, MAGENTA will pay HDPR the Research Target Fees as more fully set forth in Section 9.1.2.

Additional Targets. At any time during the Screening Period, Cubist may provide Pharmacopeia notice that Cubist wishes to drop a Target from this Agreement and designate an additional target as a Target for all purposes of this Agreement. Within fifteen (15) days of receipt of such notice, Pharmacopeia shall, at its sole discretion, accept or deny the designation of each such proposed target as a Target by notice to Cubist. Upon Pharmacopeia's notice of such acceptance, if any, Cubist's right to negotiate a further agreement with respect to such dropped Target shall terminate.

Additional Targets. (a) If, during the applicable Pathway Designation Term, OncoMed is interested in pursuing with any Third Party a potential target that, based upon [***] OncoMed believes may be in the [***] Pathway or the RSPO-LGR Pathway, it shall issue a notice to Celgene that it wishes [***] to determine in accordance with Section 2.2.9 whether or not such potential target is within the [***] Pathway or RSPO-LGR Pathway, as applicable, provided that subject to Section 2.2.8(b), for a period of [***] following the Effective Date OncoMed may not issue such a notice to Celgene, and may not add such potential target to the Excluded Target List, unless Celgene agrees in writing that such target can be considered an Excluded Target. If [***] such potential target is within the [***] Pathway, or the RSPO-LGR Pathway, as applicable, then OncoMed shall promptly notify Celgene in writing of such potential target, and such potential target shall be added to Exhibit C-1 or C-2 of this Agreement, as applicable, and shall be a RSPO Umbrella Target, or a [***] Umbrella Target, as applicable. If [***] such potential target is not within either the [***] Pathway or the RSPO-LGR Pathway, then such potential target shall not be added to Exhibit C-1 or C-2 of this Agreement and shall not be deemed a RSPO Umbrella Target, or a [***] Umbrella Target, and such potential target shall be an Excluded Target and shall be added to the Excluded Target List. (b) Notwithstanding Section 2.2.8(a), if, at any time during the applicable Pathway Designation Term, if OncoMed is required to [***] rights to any target (including a target that may be a potential target in the [***] Pathway or the RSPO-LGR Pathway) under the [***] (such target, a “[***] Additional Target”), then OncoMed shall provide written notice of such [***] Additional Target to the Gatekeeper, along with a notation that such target is an Excluded Target because it is a [***] Additional Target. Upon receipt of [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. such written notice by the Gatekeeper, such [***] Additional Target shall be deemed an Excluded Target, and shall be automatically added to the Excluded Target List. In conjunction with provision of notice to the Gatekeeper, OncoMed shall provide written notice to Celgene that it has added a target to the Excluded Target List. If ...

Additional Targets. For a period of [***] days following the Effective Date (the “Exclusivity Period”), Inspirevax agrees to exclusively negotiate with Oragenics the terms and conditions of an option agreement to license the development rights to the BDX Products as regards the [***], [***] and [***] as additional vaccine targets (the “Additional Targets”). Such option agreement would provide that, if the option is exercised, option exercise payments, milestones, and royalties would be included as a supplement to this Agreement. During the Exclusivity Period, Inspirevax agrees to not enter into a letter of intent, memorandum of understanding, agreement in principle, commitment or agreement with a person other than Oragenics relating to grant of license rights to the BDX Products in relation to the Additional Targets.